An observational study in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 20 sites in Thailand. Open to participants aged 41 Years and older. Per ClinicalTrials.gov, last updated 2012-05-31.
Sponsored by AstraZeneca · Observational
The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.
MC MD
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 684 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care and Specialty care in 20 centers nationwide in Thailand
Exclusion Criteria:
Changes in PEF and overall CCQ score
Time frame: between the first visit and after 12 (plus or minus 1) weeks
Difference of the changes of PEF and overall CCQ score comparing between various treatments
Time frame: between the first visit and after 12 (plus or minus 1) weeks
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca